INTERACTION BETWEEN THE RENIN ANGIOTENSIN SYSTEM AND α1-ADRENERGIC RECEPTORS AT THE RENAL RESISTANCE VESSELS IN DIABETES MELLITUS AND HYPERTENSION

AIDIAHMAD BIN DEWA

UNIVERSITI SAINS MALAYSIA

2007
INTERACTION BETWEEN THE RENIN ANGIOTENSIN SYSTEM AND
$\alpha_1$-ADRENERGIC RECEPTORS AT THE RENAL RESISTANCE VESSELS
IN DIABETES MELLITUS AND HYPERTENSION

by

AIDIAHMAD BIN DEWA

Thesis submitted in fulfillment of the requirements
for the degree of
Doctor of Philosophy

June 2007
ACKNOWLEDGEMENTS

AlhamduLillah, Praise to Allah Who Has Granted me the dedication and strength, and placed these wonderful people in my path on my way so that it becomes possible for me to complete the study.

First, I am enormously grateful to my sponsor, Universiti Sains Malaysia. Especially to Associate Professor (Dr.) Syed Azhar Syed Sulaiman, the Dean of School of Pharmaceutical Sciences, Universiti Sains Malaysia for having faith in my work and myself. I am indebted to my supervisors, Associate Professor Dr Munavvar Zubaid Abdul Sattar and Professor Dr Nor Azizan for their unmeasured guidance, understanding, and commitment in grooming me for the future.

I cannot do this without undivided support and love from my family, especially my father and mother, my wife (Dr. Lilis Surienty) and my children (Adib Sulaiman, Amal Solehah and Ahmad Sufyan). I am deeply grateful and indebted to them.

I would like to thank my friends, Dr. Helmi, Dr. Syed Atif, Wong Kuan Yau, Mohamed Ibrahim, Rehab, Tito, Hassaan Rathore, Fathihah, Nur Jannah, Raisa and all my JIM friends who had been there to offer friendships of all kinds for the smooth sailing of my research journey. My appreciation to Madam Yoong, Mr. Wan, Mr. Hasan, Mr. Rusli, Mr. Tan and to each one who has helped me in completing my study.

Last and not least, I am deeply grateful to Datin Hajah Fazia Ali (presently the Deputy Registrar for IPS), Mr. Ramli Osman and Madam Noorizan of USM Human Resource Department (our Academic Staff Training Scheme liaison officer) who are never short of smiles or time to assist us the ASTS along the way.
TABLE OF CONTENTS

Acknowledgements ii
Table of Contents iii
List of Tables ix
List of Figures xi
List of Abbreviations xvii
Abstrak xx
Abstract xxii

CHAPTER 1 – INTRODUCTION 1
1.1. The kidney 2
   1.1.1. The Nephron 3
      1.1.1.a. Renal Corpuscle 3
      1.1.1.b. The Tubules 5
   1.1.2 Renal Circulation 8
      1.1.2.a. Renal Regional Circulation 10
      1.1.2.b. Autoregulation of Renal Circulation 11
   1.1.3 Role of the Kidney In the Long-term Regulation of
      Arterial Pressure 15
      1.1.3.a. Medullary Circulation in the Long-term
      Regulation of the Arterial Pressure 17
      1.1.3.b. Influences of Ang II on Renal Medullary
      Circulation 19
   1.1.4. Renal Innervation 20
1.2. Resistance Vessels And Small Artery Remodelling 29
   1.2.1. Small Artery Structure 29
1.2.2. Remodelling In Human Hypertension

1.2.3. Small Artery Structure And Blood Pressure

1.2.4. Role of Renal Afferent Arterioles In the
Pathogenesis of Hypertension

1.2.5. Signaling Pathway In Vascular Remodeling

1.3. Adrenergic Receptors

1.3.1. $\alpha$-adrenoceptors

1.3.1.a. $\alpha_1$-adrenoceptor

1.3.1.b. $\alpha_2$-adrenoceptor

1.3.2. $\beta$-adrenoceptor

1.4. Renin-Angiotensin System

1.4.1. The Classical Renin-Angiotensin System

1.4.1.a. Renin

1.4.1.b. Angiotensinogen

1.4.1.c. Angiotensin Converting Enzyme

1.4.1.d. Angiotensin II

1.4.2. Angiotensin II Receptors

1.4.2.a. Angiotensin II Receptor Subtype 1

1.4.2.b. Angiotensin II Receptor Subtype 2

1.4.3. Newly Recognized Components of the RAS

1.4.3.a. Local Tissue RAS

1.4.3.a.1. Intrarenal RAS

1.4.3.a.2. Vascular RAS

1.4.3.a.3. Cardiac RAS

1.4.3.a.4. Adrenal RAS

1.4.3.a.5. Renin Receptor

1.4.3.a.6. Angiotensin Converting Enzyme 2
1.4.3.a.7. Angiotensin-(1-7) 80

1.4.3.a.8. Angiotensin Receptor Heterodimerization 82

1.4.4. Inhibitors of the Renin-Angiotensin System 85

1.5. Interaction of RAS And the Sympathetic Nervous System In the Regulation of Renal Haemodynamics. 86

1.5.1. Action Of Ang II On The Sympathetic Nervous System 86

1.5.1.a. Central Sympathetic Outflow 86

1.5.1.b. Adrenal Medulla 90

1.5.1.c. Sympathetic Ganglia 93

1.5.1.d. Sympathetic Nerve Terminal 93

1.5.1.d.1. Presynaptic Actions of Ang II 93

1.5.1.d.2. Postsynaptic Actions of Ang II 95

1.5.2. Physiological Significance of Effect of Ang II on the Sympathetic Nervous System 96

1.5.2.a. Role of Sympathetic Nervous System in Blood Pressure Response to Ang II 96

1.5.2.b. Role of Ang II in Cardiovascular Responses to Sympathetic Stimulation 96

1.5.3. Effect of Ang II on Baroreflex Control of the Heart Rate 101

1.6. Hypertension 106

1.6.1. Spontaneously Hypertensive Rats 109

1.6.2. Benefits of Lowering BP 109

1.7 Diabetes Mellitus 113

1.7.1 Classification of Diabetes Mellitus 114

1.7.2 Experimental Models of Type 1 Diabetes Mellitus 115

1.7.2.a Alloxan Induced Diabetes Mellitus 115

1.7.2.b Streptozotocin Induced Diabetes Mellitus 116
1.8 Objective of Study

CHAPTER 2 – MATERIALS AND METHODS

2.1. Experimental Animals

2.2. Induction of Diabetes Mellitus

2.3. Experimental Groups

2.3.1. Nondiabetic and Diabetic WKY and SHR

2.3.2. Perindopril and Losartan Treated Nondiabetic WKY and SHR

2.3.3. Perindopril and Losartan Treated Diabetic WKY and SHR

2.4. Acute Study

2.4.1. Experimental Protocols

2.4.2. Animal Surgical Preparation

2.4.3. Determination of Mean Arterial Pressure and Renal Blood Flow Basal Values

2.4.4. Acute Renal Vasoconstrictor Responses

2.4.5. Termination of the Experiment

2.5. Urine and Plasma Sodium (UNa⁺ and PNa⁺) Estimation

2.6. Fasting Blood Glucose

2.7. Preparations of Drugs

2.8. Lists of Chemicals

2.9. Lists of Equipments

2.10. Data Analysis

CHAPTER 3 – RESULTS

3.1. Body Weight

3.2. 24 hourly Water Intake and Urine Output
3.3. 24 hourly Urinary Sodium Excretion 136
3.4. Plasma Glucose and Sodium 137
3.5. Baseline Values of Mean Arterial Pressure 138
3.6. Baseline Values of Renal Blood Flow 139
3.7. Acute renal vasoconstrictor responses 140
3.7.1. Non-diabetic WKY 140
3.7.1.a. Renal Nerve Stimulation 140
3.7.1.b. Phenylephrine 141
3.7.1.c. Methoxamine 142
3.7.1.d. Angiotensin II 144
3.7.2. Diabetic WKY 146
3.7.2.a. Renal Nerve Stimulation 146
3.7.2.b. Phenylephrine 147
3.7.2.c. Methoxamine 148
3.7.2.d. Angiotensin II 149
3.7.3. Non-diabetic SHR 151
3.7.3.a. Renal Nerve Stimulation 151
3.7.3.b. Phenylephrine 152
3.7.3.c. Methoxamine 153
3.7.3.d. Angiotensin II 154
3.7.4. Diabetic SHR 156
3.7.4.a. Renal Nerve Stimulation 156
3.7.4.b. Phenylephrine 157
3.7.4.c. Methoxamine 159
3.7.4.d. Angiotensin II 160
3.7.5. Comparisons between different pathological conditions 161
3.7.5.a. Renal Nerve Stimulation 161
3.7.5.b. Phenylephrine 162
CHAPTER 4 – DISCUSSION

4.1. Acute effects of STZ-induced diabetic rats on metabolic data. 254

4.2. Renal vasoconstrictor responses 256
   4.2.1. Rationale of drugs used and methodology 259
   4.2.2. Choice of doses 260
   4.2.3. Functional contribution of \( \alpha_1 \)-adrenoceptors subtypes in mediating acute renal vasoconstrictor responses. 262
   4.2.3.a Acute renal vasoconstrictor responses to renal nerve stimulation. 262
   4.2.3.b Acute renal vasoconstrictor responses to phenylephrine 264
   4.2.3.c Acute renal vasoconstrictor responses to methoxamine 265
   4.2.4 Roles of endogenous circulating Ang II and AT\(_1\)-receptor in mediating acute renal vasoconstrictor responses. 265
   4.2.5 Functional interaction between \( \alpha_1 \)-adrenoceptor subtypes and renin angiotensin system in mediating acute renal vasoconstrictor responses. 267

CHAPTER 5 – CONCLUSIONS 273

BIBLIOGRAPHY 275

APPENDICES

PUBLICATION LIST
LIST OF TABLES

Table 1.1 Nomenclature for the $\alpha_1$-adrenoceptor subtypes 43
Table 1.2 Requirements for a local tissue RAS 73
Table 1.3 Interaction between renin angiotensin system (RAS), sympathetic nervous system (SNS), and baroreceptor reflex in the blood pressure control 87
Table 1.4 Classification of Blood Pressure for Adults Aged 18 Years and Older 108
Table 1.5 Lifestyle Modification to Manage Hypertension 111
Table 2.1 Experimental groups. 119
Table 2.2 Experimental regime for non-diabetic and diabetic WKY and SHR. STZ was administered only into diabetic WKY and SHR groups. 120
Table 2.3 Experimental regime for perindopril and losartan treated non-diabetic WKY and SHR. 120
Table 2.4 Experimental regime for perindopril and losartan treated diabetic WKY and SHR. Fasting blood glucose levels were measured twice to confirm the status of diabetes mellitus. 121
Table 2.5 Summary of experimental protocols. 123
Table 3.1 Base line values of mean arterial pressure in 5-MeU, CEC, BMY 7378, amlodipine, control, perindopril and losartan treated non-diabetic and diabetic WKY and SHR rats. 166
Table 3.2 Base line values of renal blood flow in 5-MeU, CEC, BMY 7378, amlodipine, control, perindopril and losartan treated non-diabetic and diabetic WKY and SHR rats. 167
Table 3.3 The average percentage decrease in renal blood flow induced by RNS in 5-MeU, CEC, BMY 7378, amlodipine, control, perindopril and losartan treated non-diabetic and diabetic WKY and SHR rats. 168
Table 3.4 The average percentage decrease in renal blood flow induced by PE in 5-MeU, CEC, BMY 7378, amlodipine, control, perindopril and losartan treated non-diabetic and diabetic WKY and SHR rats. 169
Table 3.5  The average percentage decrease in renal blood flow induced by ME in 5-MeU, CEC, BMY 7378, amlodipine, control, perindopril and losartan treated non-diabetic and diabetic WKY and SHR rats.

Table 3.6  The average percentage decrease in renal blood flow induced by Ang II in 5-MeU, CEC, BMY 7378, amlodipine, control, perindopril and losartan treated non-diabetic and diabetic WKY and SHR rats.
<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1.1</td>
<td>Gross anatomy of the kidney</td>
<td>3</td>
</tr>
<tr>
<td>Figure 1.2</td>
<td>Renal corpuscle and the ultrafiltration process</td>
<td>4</td>
</tr>
<tr>
<td>Figure 1.3</td>
<td>Nephron</td>
<td>6</td>
</tr>
<tr>
<td>Figure 1.4</td>
<td>Renal microcirculation into the regions of renal cortex (C), the outer stripe of the outer medulla (OS), the inner stripe of the outer medulla, and the inner medulla (IM).</td>
<td>9</td>
</tr>
<tr>
<td>Figure 1.5</td>
<td>Hypertropic and eutrophic remodelling of small artery.</td>
<td>32</td>
</tr>
<tr>
<td>Figure 1.6</td>
<td>Signal transduction pathways for mechanical stress in rat mesenteric small arteries.</td>
<td>37</td>
</tr>
<tr>
<td>Figure 1.7</td>
<td>Division of adrenoceptors from the early conception to the present classification.</td>
<td>53</td>
</tr>
<tr>
<td>Figure 1.8</td>
<td>Schematic representation of the classical RAS</td>
<td>56</td>
</tr>
<tr>
<td>Figure 1.9</td>
<td>The juxtaglomerular apparatus</td>
<td>58</td>
</tr>
<tr>
<td>Figure 1.10</td>
<td>Schematic representation of the newly recognised components of the RAS</td>
<td>84</td>
</tr>
<tr>
<td>Figure 2.1</td>
<td>Simplified experimental protocol for animals treated with 5-methylurapidil, chloroethylclonidine, BMY 7378 and amlodipine</td>
<td>125</td>
</tr>
<tr>
<td>Figure 2.2</td>
<td>Simplified experimental protocol for animals treated with perindopril, losartan and the control groups.</td>
<td>126</td>
</tr>
<tr>
<td>Figure 3.1</td>
<td>Body weight in non-diabetic and diabetic WKY and SHR rats.</td>
<td>172</td>
</tr>
<tr>
<td>Figure 3.2</td>
<td>Body weight in perindopril and losartan treated non-diabetic WKY and SHR rats.</td>
<td>173</td>
</tr>
<tr>
<td>Figure 3.3</td>
<td>Body weight in perindopril and losartan treated diabetic WKY and SHR rats.</td>
<td>174</td>
</tr>
<tr>
<td>Figure 3.4</td>
<td>Overall mean of water intake in non-diabetic and diabetic WKY and SHR rats.</td>
<td>175</td>
</tr>
<tr>
<td>Figure 3.5</td>
<td>24 hourly water intake in perindopril and losartan treated non-diabetic WKY and SHR rats.</td>
<td>176</td>
</tr>
<tr>
<td>Figure 3.6</td>
<td>24 hourly water intake in perindopril and losartan treated diabetic WKY and SHR rats.</td>
<td>177</td>
</tr>
<tr>
<td>Figure 3.7</td>
<td>Overall mean of urine output in non-diabetic and diabetic WKY and SHR rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.8</td>
<td>24 hourly urine output in perindopril and losartan treated non-diabetic WKY and SHR rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.9</td>
<td>24 hourly urine output in perindopril and losartan treated diabetic WKY and SHR rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.10</td>
<td>Overall mean of urinary sodium excretion in non-diabetic and diabetic WKY and SHR rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.11</td>
<td>24 hourly urinary sodium excretion in perindopril and losartan treated non-diabetic WKY and SHR rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.12</td>
<td>24 hourly urinary sodium excretion in perindopril and losartan treated diabetic WKY and SHR rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.13</td>
<td>Level of plasma sodium in control, perindopril and losartan treated non-diabetic and diabetic WKY and SHR rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.14</td>
<td>Level of plasma glucose in non-diabetic and diabetic WKY and SHR rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.15</td>
<td>The overall percentage decrease in renal blood flow to RNS in 5-MeU, CEC, BMY 7378, amlodipine, control, perindopril and losartan treated WKY and SHR rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.16</td>
<td>The overall percentage decrease in renal blood flow to PE in 5-MeU, CEC, BMY 7378, amlodipine, control, perindopril and losartan treated WKY and SHR rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.17</td>
<td>The overall percentage decrease in renal blood flow to ME in 5-MeU, CEC, BMY 7378, amlodipine, control, perindopril and losartan treated WKY and SHR rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.18</td>
<td>The overall percentage decrease in renal blood flow to Ang II in 5-MeU, CEC, BMY 7378, amlodipine, control, perindopril and losartan treated WKY and SHR rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.19</td>
<td>Renal vasoconstrictor responses to RNS in the absence and the presence of 5 and 10 ug.kg(^{-1}) of 5-MeU in non-diabetic and diabetic WKY rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.20</td>
<td>Renal vasoconstrictor responses to RNS in the absence and the presence of 5 and 10 ug.kg(^{-1}) of 5-MeU in non-diabetic and diabetic SHR rats.</td>
<td></td>
</tr>
<tr>
<td>Figure 3.21</td>
<td>Renal vasoconstrictor responses to RNS in the absence and the presence of 5 and 10 ug.kg(^{-1}) of CEC in non-diabetic and diabetic WKY rats.</td>
<td></td>
</tr>
</tbody>
</table>
Figure 3.22 Renal vasoconstrictor responses to RNS in the absence and the presence of 5 and 10 ug.kg^{-1} of CEC in non-diabetic and diabetic SHR rats.

Figure 3.23 Renal vasoconstrictor responses to RNS in the absence and the presence of 100 and 200 ug.kg^{-1} of BMY 7378 in non-diabetic and diabetic WKY rats.

Figure 3.24 Renal vasoconstrictor responses to RNS in the absence and the presence of 100 and 200 ug.kg^{-1} of BMY 7378 in non-diabetic and diabetic SHR rats.

Figure 3.25 Renal vasoconstrictor responses to RNS in the absence and the presence of 200 and 400 ug.kg^{-1} of amlodipine in non-diabetic and diabetic WKY rats.

Figure 3.26 Renal vasoconstrictor responses to RNS in the absence and the presence of 200 and 400 ug.kg^{-1} of amlodipine in non-diabetic and diabetic SHR rats.

Figure 3.27 Renal vasoconstrictor responses to RNS in the control groups of non-diabetic and diabetic WKY rats.

Figure 3.28 Renal vasoconstrictor responses to RNS in the control groups of non-diabetic and diabetic SHR rats.

Figure 3.29 Renal vasoconstrictor responses to RNS in the perindopril-treated non-diabetic and diabetic WKY rats.

Figure 3.30 Renal vasoconstrictor responses to RNS in the perindopril-treated non-diabetic and diabetic SHR rats.

Figure 3.31 Renal vasoconstrictor responses to RNS in the losartan-treated non-diabetic and diabetic WKY rats.

Figure 3.32 Renal vasoconstrictor responses to RNS in the losartan-treated non-diabetic and diabetic SHR rats.

Figure 3.33 Renal vasoconstrictor responses to PE in the absence and the presence of 5 and 10 ug.kg^{-1} of 5-MeU in non-diabetic and diabetic WKY rats.

Figure 3.34 Renal vasoconstrictor responses to PE in the absence and the presence of 5 and 10 ug.kg^{-1} of 5-MeU in non-diabetic and diabetic SHR rats.

Figure 3.35 Renal vasoconstrictor responses to PE in the absence and the presence of 5 and 10 ug.kg^{-1} of CEC in non-diabetic and diabetic WKY rats.

Figure 3.36 Renal vasoconstrictor responses to PE in the absence and the presence of 5 and 10 ug.kg^{-1} of CEC in non-diabetic and diabetic SHR rats.
Figure 3.37 Renal vasoconstrictor responses to PE in the absence and the presence of 100 and 200 ug.kg\(^{-1}\) of BMY 7378 in non-diabetic and diabetic WKY rats.

Figure 3.38 Renal vasoconstrictor responses to PE in the absence and the presence of 100 and 200 ug.kg\(^{-1}\) of BMY 7378 in non-diabetic and diabetic SHR rats.

Figure 3.39 Renal vasoconstrictor responses to PE in the absence and the presence of 200 and 400 ug.kg\(^{-1}\) of amlodipine in non-diabetic and diabetic WKY rats.

Figure 3.40 Renal vasoconstrictor responses to PE in the absence and the presence of 200 and 400 ug.kg\(^{-1}\) of amlodipine in non-diabetic and diabetic SHR rats.

Figure 3.41 Renal vasoconstrictor responses to PE in the control groups of non-diabetic and diabetic WKY rats.

Figure 3.42 Renal vasoconstrictor responses to PE in the control groups of non-diabetic and diabetic SHR rats.

Figure 3.43 Renal vasoconstrictor responses to PE in the perindopril-treated non-diabetic and diabetic WKY rats.

Figure 3.44 Renal vasoconstrictor responses to PE in the perindopril-treated non-diabetic and diabetic SHR rats.

Figure 3.45 Renal vasoconstrictor responses to PE in the losartan-treated non-diabetic and diabetic WKY rats.

Figure 3.46 Renal vasoconstrictor responses to PE in the losartan-treated non-diabetic and diabetic SHR rats.

Figure 3.47 Renal vasoconstrictor responses to ME in the absence and the presence of 5 and 10 ug.kg\(^{-1}\) of 5-MeU in non-diabetic and diabetic WKY rats.

Figure 3.48 Renal vasoconstrictor responses to ME in the absence and the presence of 5 and 10 ug.kg\(^{-1}\) of 5-MeU in non-diabetic and diabetic SHR rats.

Figure 3.49 Renal vasoconstrictor responses to ME in the absence and the presence of 5 and 10 ug.kg\(^{-1}\) of CEC in non-diabetic and diabetic WKY rats.

Figure 3.50 Renal vasoconstrictor responses to ME in the absence and the presence of 5 and 10 ug.kg\(^{-1}\) of CEC in non-diabetic and diabetic SHR rats.

Figure 3.51 Renal vasoconstrictor responses to ME in the absence and the presence of 100 and 200 ug.kg\(^{-1}\) of BMY 7378 in non-diabetic and diabetic WKY rats.
Figure 3.52 Renal vasoconstrictor responses to ME in the absence and the presence of 100 and 200 ug.kg⁻¹ of BMY 7378 in non-diabetic and diabetic SHR rats. 223

Figure 3.53 Renal vasoconstrictor responses to ME in the absence and the presence of 200 and 400 ug.kg⁻¹ of amlodipine in non-diabetic and diabetic WKY rats. 224

Figure 3.54 Renal vasoconstrictor responses to ME in the absence and the presence of 200 and 400 ug.kg⁻¹ of amlodipine in non-diabetic and diabetic SHR rats. 225

Figure 3.55 Renal vasoconstrictor responses to ME in the control groups of non-diabetic and diabetic WKY rats. 226

Figure 3.56 Renal vasoconstrictor responses to ME in the control groups of non-diabetic and diabetic SHR rats. 227

Figure 3.57 Renal vasoconstrictor responses to ME in the perindopril-treated non-diabetic and diabetic WKY rats. 228

Figure 3.58 Renal vasoconstrictor responses to ME in the perindopril-treated non-diabetic and diabetic SHR rats. 229

Figure 3.59 Renal vasoconstrictor responses to ME in the losartan-treated non-diabetic and diabetic WKY rats. 230

Figure 3.60 Renal vasoconstrictor responses to ME in the losartan-treated non-diabetic and diabetic SHR rats. 231

Figure 3.61 Renal vasoconstrictor responses to Ang II in the absence and the presence of 5 and 10 ug.kg⁻¹ of 5-MeU in non-diabetic and diabetic WKY rats. 232

Figure 3.62 Renal vasoconstrictor responses to Ang II in the absence and the presence of 5 and 10 ug.kg⁻¹ of 5-MeU in non-diabetic and diabetic SHR rats. 233

Figure 3.63 Renal vasoconstrictor responses to Ang II in the absence and the presence of 5 and 10 ug.kg⁻¹ of CEC in non-diabetic and diabetic WKY rats. 234

Figure 3.64 Renal vasoconstrictor responses to Ang II in the absence and the presence of 5 and 10 ug.kg⁻¹ of CEC in non-diabetic and diabetic SHR rats. 235

Figure 3.65 Renal vasoconstrictor responses to Ang II in the absence and the presence of 100 and 200 ug.kg⁻¹ of BMY 7378 in non-diabetic and diabetic WKY rats. 236

Figure 3.66 Renal vasoconstrictor responses to Ang II in the absence and the presence of 100 and 200 ug.kg⁻¹ of BMY 7378 in non-diabetic and diabetic SHR rats. 237
Figure 3.67 Renal vasoconstrictor responses to Ang II in the absence and the presence of 200 and 400 ug.kg$^{-1}$ of amlodipine in non-diabetic and diabetic WKY rats.

Figure 3.68 Renal vasoconstrictor responses to Ang II in the absence and the presence of 200 and 400 ug.kg$^{-1}$ of amlodipine in non-diabetic and diabetic SHR rats.

Figure 3.69 Renal vasoconstrictor responses to Ang II in the control groups of non-diabetic and diabetic WKY rats.

Figure 3.70 Renal vasoconstrictor responses to Ang II in the control groups of non-diabetic and diabetic SHR rats.

Figure 3.71 Renal vasoconstrictor responses to Ang II in the perindopril-treated non-diabetic and diabetic WKY rats.

Figure 3.72 Renal vasoconstrictor responses to Ang II in the perindopril-treated non-diabetic and diabetic SHR rats.

Figure 3.73 Renal vasoconstrictor responses to Ang II in the losartan-treated non-diabetic and diabetic WKY rats.

Figure 3.74 Renal vasoconstrictor responses to Ang II in the losartan-treated non-diabetic and diabetic SHR rats.

Figure 3.75 The overall percentage decrease in renal blood flow to RNS in control, perindopril and losartan treated non-diabetic and diabetic WKY and SHR rats.

Figure 3.76 The overall percentage decrease in renal blood flow to PE in control, perindopril and losartan treated non-diabetic and diabetic WKY and SHR rats.

Figure 3.77 The overall percentage decrease in renal blood flow to ME in control, perindopril and losartan treated non-diabetic and diabetic WKY and SHR rats.

Figure 3.78 The overall percentage decrease in renal blood flow to Ang II in control, perindopril and losartan treated non-diabetic and diabetic WKY and SHR rats.
# LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \alpha )</td>
<td>alpha</td>
</tr>
<tr>
<td>( \beta )</td>
<td>beta</td>
</tr>
<tr>
<td>( \gamma )</td>
<td>gamma</td>
</tr>
<tr>
<td>( \mu g )</td>
<td>microgram</td>
</tr>
<tr>
<td>2K1C</td>
<td>two kidney one clip</td>
</tr>
<tr>
<td>5-Meu</td>
<td>5-methylurapidil</td>
</tr>
<tr>
<td>7-NI</td>
<td>7-nitroindazole</td>
</tr>
<tr>
<td>ANOVA</td>
<td>analysis of variance</td>
</tr>
<tr>
<td>Ang</td>
<td>angiotensin</td>
</tr>
<tr>
<td>Ang I</td>
<td>angiotensin I</td>
</tr>
<tr>
<td>Ang II</td>
<td>angiotensin II</td>
</tr>
<tr>
<td>ACE</td>
<td>angiotensin converting enzyme</td>
</tr>
<tr>
<td>ACEi</td>
<td>angiotensin converting enzyme inhibitor</td>
</tr>
<tr>
<td>ACTH</td>
<td>adrenocorticohptic hormone</td>
</tr>
<tr>
<td>AT</td>
<td>angiotensin II receptor subtype</td>
</tr>
<tr>
<td>ATP</td>
<td>adenosine triphosphate</td>
</tr>
<tr>
<td>ATPase</td>
<td>adenosine triphosphatase</td>
</tr>
<tr>
<td>ARB</td>
<td>angiotensin receptor blocker</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>BK</td>
<td>bradykinin</td>
</tr>
<tr>
<td>BW</td>
<td>body weight</td>
</tr>
<tr>
<td>cAMP</td>
<td>cyclic adenosine monophosphate</td>
</tr>
<tr>
<td>CVLM</td>
<td>caudal ventrolateral medulla</td>
</tr>
<tr>
<td>CBF</td>
<td>cortical blood flow</td>
</tr>
<tr>
<td>CCB</td>
<td>calcium channel blocker</td>
</tr>
<tr>
<td>CEC</td>
<td>chloroethylclonidine</td>
</tr>
<tr>
<td>cGMP</td>
<td>cyclic guanine monophosphate</td>
</tr>
<tr>
<td>CHF</td>
<td>congestive heart failure</td>
</tr>
<tr>
<td>CVD</td>
<td>cardiovascular disease</td>
</tr>
<tr>
<td>DAG</td>
<td>diacylglycerol</td>
</tr>
<tr>
<td>DLosSHR</td>
<td>diabetic losartan treated SHR</td>
</tr>
<tr>
<td>DLosWKY</td>
<td>diabetic losartan treated WKY</td>
</tr>
<tr>
<td>DM</td>
<td>diabetes mellitus</td>
</tr>
<tr>
<td>DPerSHR</td>
<td>diabetic perindopril treated SHR</td>
</tr>
<tr>
<td>DPerWKY</td>
<td>diabetic perindopril treated WKY</td>
</tr>
<tr>
<td>DSHR</td>
<td>diabetic SHR</td>
</tr>
<tr>
<td>DVR</td>
<td>descending vasa recta</td>
</tr>
<tr>
<td>DWKY</td>
<td>diabetic WKY</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>ECDCDM</td>
<td>The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</td>
</tr>
<tr>
<td>ERK 1/2</td>
<td>extracellular signal-regulated kinase 1 and 2</td>
</tr>
<tr>
<td>ESRF</td>
<td>end stage renal failure</td>
</tr>
<tr>
<td>et al.</td>
<td>and others</td>
</tr>
<tr>
<td>F1-SHR/WKY</td>
<td>first generation of cross breeding of SHR and WKY rats</td>
</tr>
<tr>
<td>F2-SHR/WKY</td>
<td>offspring of F1-SHR/WKY rats inbreeding</td>
</tr>
<tr>
<td>g</td>
<td>gram</td>
</tr>
<tr>
<td>GDM</td>
<td>gestational diabetes mellitus</td>
</tr>
<tr>
<td>GFR</td>
<td>glomerular filtration rate</td>
</tr>
<tr>
<td>HCO₃⁻</td>
<td>hydrogen bicarbonate ions</td>
</tr>
<tr>
<td>I cells</td>
<td>intercalated cells</td>
</tr>
<tr>
<td>i.p.</td>
<td>intraperitoneally</td>
</tr>
<tr>
<td>i.v.</td>
<td>intravenously</td>
</tr>
<tr>
<td>IGF</td>
<td>insulin-like growth factor</td>
</tr>
<tr>
<td>IP₃</td>
<td>inositol triphosphate</td>
</tr>
<tr>
<td>JGC</td>
<td>juxtaglomerular cell</td>
</tr>
<tr>
<td>kg</td>
<td>kilogram</td>
</tr>
<tr>
<td>L-NAME</td>
<td>N(G)-nitro-L-arginine methyl ester</td>
</tr>
<tr>
<td>MAP</td>
<td>mean arterial pressure</td>
</tr>
<tr>
<td>MBF</td>
<td>medullary blood flow</td>
</tr>
<tr>
<td>ME</td>
<td>methoxamine</td>
</tr>
<tr>
<td>mEA</td>
<td>muscular efferent arterioles</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>mg.dl⁻¹</td>
<td>milligram per deciliter</td>
</tr>
<tr>
<td>mg.kg⁻¹</td>
<td>milligram per kilogram</td>
</tr>
<tr>
<td>ml</td>
<td>milliliter</td>
</tr>
<tr>
<td>ml.min⁻¹.kg⁻¹</td>
<td>milliliter per minute per kilogram</td>
</tr>
<tr>
<td>mmHg</td>
<td>millimeter mercury</td>
</tr>
<tr>
<td>MMP</td>
<td>matrix metalloproteinase</td>
</tr>
<tr>
<td>mmol.dl⁻¹</td>
<td>millimolar per deciliter</td>
</tr>
<tr>
<td>mRNA</td>
<td>messenger ribonucleic acid</td>
</tr>
<tr>
<td>n</td>
<td>number of animals</td>
</tr>
<tr>
<td>NA</td>
<td>noradrenaline</td>
</tr>
<tr>
<td>NdLosSHR</td>
<td>nondiabetic losartan SHR</td>
</tr>
<tr>
<td>NdLosWKY</td>
<td>nondiabetic losartan WKY</td>
</tr>
<tr>
<td>NdPerSHR</td>
<td>nondiabetic perindopril treated SHR</td>
</tr>
<tr>
<td>NdPerWKY</td>
<td>nondiabetic perindopril treated WKY</td>
</tr>
<tr>
<td>NdSHR</td>
<td>nondiabetic SHR</td>
</tr>
<tr>
<td>NdWKY</td>
<td>nondiabetic WKY</td>
</tr>
<tr>
<td>NEP</td>
<td>neutral-endopeptidase</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Name</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>ng</td>
<td>nanogram</td>
</tr>
<tr>
<td>NO</td>
<td>nitric oxide</td>
</tr>
<tr>
<td>NOS</td>
<td>nitric oxide synthase</td>
</tr>
<tr>
<td>NTS</td>
<td>nucleus of solitary tract</td>
</tr>
<tr>
<td>P-cell</td>
<td>principal cells</td>
</tr>
<tr>
<td>PCP</td>
<td>prolyl-carboxypeptidase</td>
</tr>
<tr>
<td>PDCF</td>
<td>platelet-derived growth factor</td>
</tr>
<tr>
<td>PDE</td>
<td>phosphodiesterase</td>
</tr>
<tr>
<td>PE</td>
<td>phenylephrine</td>
</tr>
<tr>
<td>PEP</td>
<td>prolyl-endopeptidase</td>
</tr>
<tr>
<td>PG</td>
<td>plasma glucose</td>
</tr>
<tr>
<td>PGE₂</td>
<td>prostaglandin E₂</td>
</tr>
<tr>
<td>PGF₂α</td>
<td>prostaglandin F₂α</td>
</tr>
<tr>
<td>Pgc</td>
<td>glomerular capillary pressure</td>
</tr>
<tr>
<td>PIP₂</td>
<td>phosphatidylinositol biphosphate</td>
</tr>
<tr>
<td>PKC</td>
<td>protein kinase C</td>
</tr>
<tr>
<td>PNa⁺</td>
<td>plasma sodium</td>
</tr>
<tr>
<td>RAS</td>
<td>renin angiotensin system</td>
</tr>
<tr>
<td>RANTES</td>
<td>Regulated upon Activation, Normal T-cell Expressed, and Secreted</td>
</tr>
<tr>
<td>RBF</td>
<td>renal blood flow</td>
</tr>
<tr>
<td>RNS</td>
<td>renal nerve stimulation</td>
</tr>
<tr>
<td>RPP</td>
<td>renal perfusion pressure</td>
</tr>
<tr>
<td>RSNA</td>
<td>renal sympathetic nerve activity</td>
</tr>
<tr>
<td>RT-PCR</td>
<td>reverse transcriptase-polymerase chain reaction</td>
</tr>
<tr>
<td>RVLM</td>
<td>rostral excitory region of the ventrolateral medulla</td>
</tr>
<tr>
<td>RVR</td>
<td>renal vascular resistance</td>
</tr>
<tr>
<td>SD</td>
<td>Sprague Dawley</td>
</tr>
<tr>
<td>SHR</td>
<td>spontaneously hypertensive rat</td>
</tr>
<tr>
<td>SNS</td>
<td>sympathetic nervous system</td>
</tr>
<tr>
<td>STZ</td>
<td>streptozotocin</td>
</tr>
<tr>
<td>tEA</td>
<td>thin efferent arterioles</td>
</tr>
<tr>
<td>T₁DM</td>
<td>type 1 diabetes mellitus</td>
</tr>
<tr>
<td>T₂DM</td>
<td>type 2 diabetes mellitus</td>
</tr>
<tr>
<td>TGF</td>
<td>tubuloglomerular feedback</td>
</tr>
<tr>
<td>TGFi²</td>
<td>tumor growth factor</td>
</tr>
<tr>
<td>UNa⁺</td>
<td>urinary sodium</td>
</tr>
<tr>
<td>UO</td>
<td>urine output</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WI</td>
<td>water intake</td>
</tr>
<tr>
<td>WKY</td>
<td>Wistar Kyoto</td>
</tr>
</tbody>
</table>
α₁-adrenoseptor dan reseptor subjenis angiotensin jenis 1 (AT₁) memainkan peranan penting dalam pengawalaturan hemodinamik ginjal pada peringkat vaskulatur rintangan ginjal. Ianya memang diketahui yang diabetis melitus mampu merosakkan salur darah dan saraf periferi, dan ini diburukkan lagi oleh keadaan darah tinggi. Kajian ini dilakukan bagi mengkaji peranan fungsi subjenis α₁-adrenoseptor dan reseptor AT₁ pada peringkat vaskulatur rintangan ginjal dalam diabetis melitus, darah tinggi, dan gabungan kedua-dua keadaan patologikal, dan sebarang kemungkinan interaksi fungsi intrarenal antara α₁-adrenoceptors dan renin angiotensin setempat. Tikus normotensif WKY dan SHR telah digunakan. Diabetis mellitus diaruh dengan satu dos tunggal streptozotosin pada 55 mg.kg⁻¹ secara intraperitoneal. Berat badan, jumlah air diminum, jumlah air kencing, paras glukosa dan natrium darah, dan tahap penyingkiran natrium melalui air kencing dimantau. Semasa kajian akut, tikus-tikus ini dibius dengan natrium pentobarbiton pada 60 mg.kg⁻¹ secara intraperitoneal. Lanjutan trakeostomi untuk membolehkan pernafasan berbantu, vena jugular kiri dan arteri karotid kanan dimasuk tiub bagi tujuan pemberian berterusan air salin dan pengukuran tekanan darah arteri purata. Selesai melakukan pembelahan abdomen garis tengah, organ dalaman abdomen dialihkan secara berhati-hati ke sebelah kanan bagi mendedahkan ginjal kiri. Satu prob pengaliran elektromagnetik dipasang pada arteri renal untuk pengukuran pengaliran darah ginjal. Elektrod dwipolar digunakan untuk merangsang saraf renal. Sebaik sahaja pembedahan selesai, 2 ml salin diberi secara intravena sebagai primer, dan tikus distabilkan untuk tempoh satu jam. Pengurangan pengaliran darah ginjal terhadap rangsangan saraf elektrikal (1, 2, 4, 6, 8 dan 10 Hz pada 15V, 2 ms), dos bolus fenilefrin (0.25, 0.50, 1.00 dan 2.00 μg), metoksamin (0.50, 1.00, 2.00
dan 4.00 μg) dan angiotensin II (2.50, 5.00, 10.00 dan 20.00 ng) ditentukan dalam kehadiran 5-metilurapidil (5.00 dan 10.00 μg.kg⁻¹ termasuk 1.25 dan 2.50 μg.kg⁻¹.hr⁻¹), kloroetiklonidin (5.00 dan 10.00 μg.kg⁻¹ termasuk 1.25 dan 2.50 μg.kg⁻¹.hr⁻¹), BMY7378 (100.00 dan 200.00 μg.kg⁻¹ termasuk 25.00 dan 50.00 μg.kg⁻¹.hr⁻¹), amlodipin (200.00 dan 400.00 μg.kg⁻¹ termasuk 50.00 dan 100.00 μg.kg⁻¹.hr⁻¹), perindopril (0.20 mg.kg⁻¹) dan losartan (10.00 mg.kg⁻¹), dan tekanan darah arteri purata dimantau. Data, purata ± s.e.m., dianalisis dengan ANOVA-satu hala atau -dua hala diikuti dengan post-hoc Bonferroni pada tahap signifikan 5%. Pengurangan secara signifikan dalam berat badan, peningkatan ketara air diminum dan penghasilan air kencing diperhatikan di dalam haiwan diabetik berbanding dengan haiwan tidak diabetik. Nilai asas tekanan darah arteri purata kekal konsisten sepanjang kajian kecuali di dalam beberapa kumpulan, manakala nilai asas pengaliran darah renal kekal tidak berubah di dalam kesemua kumpulan ujian. Dari respon vasokonstriktor renal, subjenis α₁A adrenoseptor dan reseptor pos-sinaptik AT₁ memainkan peranan penting dalam mengawalatur vasokonstriksi salur darah rintangan dalam tikus WKY dan SHR bukan diabetik dan diabetik. Fungsi adrenoseptor subjenis α₁B and α₁D, dan Ang II beraliran amat dipengaruhi oleh keadaan penyakit diabetis melitus dan tekanan darah tinggi. Dalam tikus nondiabetik WKY, interaksi di antara sistem renin angiotensin dan adrenoseptor subjenis α₁ berlaku secara utama melalui adrenoseptor subjenis α₁B dan reseptor AT₁, dan di bawah pengaruh diabetis melitus dan tekanan darah tinggi adrenoseptor subjenis α₁A dan α₁D menjadi lebih terlibat di dalam interaksi ini. Ang II beraliran mempunyai kesan lebih ketara ke atas respon dimediasi oleh adrenoseptor α₁ berbanding oleh reseptor AT₁. Kesimpulannya, interaksi dalam ginjal di antara reseptor adrenergik α₁ dan reseptor AT₁ wujud pada peringkat salur darah rintangan ginjal, dan ini dipengaruhi secara ketara oleh keadaan penyakit diabetis melitus dan tekanan darah tinggi.
α₁-adrenoceptors and angiotensin type 1 (AT₁) receptor subtype play important roles in the regulation of renal haemodynamic at the level of renal resistance vasculature. It is known that diabetes mellitus could damage the peripheral blood vessels and nerves, and is worsened by hypertensive state. This study was designed to examine the functional role of α₁-adrenoceptor subtypes and AT₁-receptor at the renal vasculature resistance in diabetes mellitus, hypertension and combination of both pathological states, and any possible intrarenal functional interaction between the α₁-adrenoceptors and local renin-angiotensin systems. Normotensive WKY and SHR rats were utilized. Diabetes mellitus was induced by a single dose of streptozotocin at 55 mg.kg⁻¹ intraperitoneally. Body weight, water intake, urine output, plasma glucose and sodium levels, and urinary sodium excretion were monitored. During the acute study, the rats were anaesthetized with pentobarbitone sodium at 60 mg.kg⁻¹ intraperitoneally. Following tracheostomy to allow facilitated breathing, the left jugular vein and the right carotid artery were cannulated for continuous infusion of saline and measurement of the mean arterial blood pressure, respectively. Having performed a midline abdominal incision, the internal abdominal organs were carefully displaced to the right side to expose the left kidney. An electromagnetic flow probe was placed on the renal artery for renal blood flow (RBF) measurement. Bipolar electrodes were used to stimulate renal nerve. Upon completion of surgery, 2 ml of saline was given intravenously as a primer, and one hour period of stabilization was observed. Reductions in RBF to electrical stimulation (1, 2, 4, 6, 8, and 10 Hz at 15V, 2 ms), bolus doses of phenylephrine (0.25, 0.50, 1.00 and 2.00 μg), methoxamine (0.50, 1.00, 2.00 and 4.00 μg) and angiotensin II (2.50, 5.00, 10.00 and 20.00 ng) were determined in the
presence of 5-methylurapidil (5.00 and 10.00 μg.kg⁻¹ plus 1.25 and 2.50 μg.kg⁻¹.hr⁻¹), chloroethylclonidine (5.00 and 10.00 μg.kg⁻¹ plus 1.25 and 2.50 μg.kg⁻¹.hr⁻¹), BMY7378 (100.00 and 200.00 μg.kg⁻¹ plus 25.00 and 50.00 μg.kg⁻¹.hr⁻¹), amlodipine (200.00 and 400.00 μg.kg⁻¹ plus 50.00 and 100.00 μg.kg⁻¹.hr⁻¹), perindopril (0.20 mg.kg⁻¹) and losartan (10.00 mg.kg⁻¹), and mean arterial pressure (MAP) were monitored. Data, means ± s.e.m., were analyzed with one- and two-ways analysis of variance followed by Bonferroni post hoc with the significance level of 5%. Significant reductions in body weight, higher water intake and urine output were observed in diabetic as compared to nondiabetic animals. Baseline values of MAP remained consistent throughout study except in few groups, whereas the RBF values remained unaltered in all experimental groups. From the renal vasoconstrictor responses, the α₁A-adrenoceptor subtype and postsynaptic AT₁-receptors are functionally important in mediating the vasoconstriction of the resistance vessels in nondiabetic and diabetic WKY and SHR rats. Functionality of α₁B- and α₁D-adrenoceptor subtypes and circulating Ang II were greatly influenced by the pathological states of diabetes mellitus and hypertension. In nondiabetic WKY, the interaction between the renin angiotensin system and α₁-adrenoceptor subtypes occurred mainly through α₁B-adrenoceptor subtype and AT₁-receptor, and under the influence of diabetic and hypertensive conditions, the α₁A- and α₁D-adrenoceptor subtypes became increasingly involved in the interaction. Circulating Ang II exerted greater effects on the responses mediated by α₁-adrenergic receptors than by AT₁-receptors. In conclusion, intrarenal interaction between the α₁-adrenergic receptors and AT₁-receptor exists at the level of renal resistance vessels, and this is greatly influenced by the pathological conditions of diabetes mellitus and hypertension.
CHAPTER 1

INTRODUCTION

The maintenance of cardiovascular homeostasis represents a balance between the volume of blood in the vascular system, the pumping effectiveness of the heart, the regulation of arterial vascular resistance and the function of the kidney to ensure appropriate level of fluid reabsorption and excretion. Dysfunction of any one element of this cardiovascular-renal control interaction can be responsible for the development of a chronically elevated blood pressure (BP), or hypertension which exists in up to 20% of the adult population of most developed nations (Genest, 1994). The sustained elevated BPs impose a burden on the cardiovascular system, in particular on arteries, arterial resistance vessels, the cerebrovascular circulation, the heart and the kidneys, and places these individuals at increased risk of target-organ damages, such as stroke, myocardial infarction, left ventricular hypertrophy, heart failure and end-stage renal failure (ESRF) (Chobanian et al., 2003).

A dramatic increase in patients with ESRF has been observed. In 1991, about 190,000 persons in the United States either underwent dialysis or received a renal transplant for ESRF (Klag et al., 1996), and the major underlying causes were diabetic nephropathy and high BP. High BP is a strong independent risk factor for ESRF. The increase in risk associated with higher BP is graded and continuous throughout the distribution of blood pressure readings above the optimal level. The risk of ESRF in men with hypertension, as compared with men with optimal levels of BP, increases with each of the four successively more severe stages of hypertension. Systolic BP before treatment is a stronger predictor of end-stage renal disease than is diastolic pressure. Overall, the rates of ESRF are markedly higher for men with hypertensive levels of both systolic and diastolic BP (Klag et al., 1996). Observational and clinical
trials involving patients with renal insufficiency have also demonstrated that lowering BP preserves renal function.

The central role of the kidney in the regulation of BP in many pathophysiological conditions has been supported by the experimental work of Guyton (1989) and the clinical evidence of Hollenberg (1980) who reported that in young essential hypertensive patients, up to two thirds could be shown to have either, or both, a slight reduction in renal blood flow or defective ability to excrete a saline volume load. Among the contributable factors are increased activity of the renin-angiotensin system and the renal sympathetic nervous system. Over-activation of these systems leads to retention of sodium and water, and increased vasoconstriction of peripheral resistance vessels that increases the vascular resistance against the blood flow, and thus the BP.

1.1 The kidney

The kidney is one of the vital organs of the body, and plays important roles in maintaining the internal environment of the body within its optimal condition. The kidney performs a variety of functions as below:

1. Regulation of water, inorganic ion balance and internal environment,
2. Removal of metabolic waste products, such as urea, uric acid and creatinine, from the blood and their excretion in the urine,
3. Removal of foreign chemicals, such as drugs, pesticides, food additives, from the blood and their excretion in the urine,
4. Synthesizing glucose from amino acids and other precursors to be released into the blood during prolonged fasting (gluconeogenesis),
5. Production of hormones/enzymes:
   - Erythropoietin, which controls erythrocyte production (erythropoiesis),
   - Renin, an enzyme that controls the formation of angiotensin and involves in the regulation of blood pressure and sodium balance,
   - 1,25-dihydroxyvitamin D, which influences calcium balance.
1.1.1 The nephron

The single functional unit of the kidney is nephron, and there are approximately 1 million nephrons in each kidney. Each nephron is made of a renal corpuscle and a tubule that extends from the renal corpuscle. The renal corpuscle is the initial filtering component of the kidney, forming filtrate from blood that is free from cells and protein. The filtrate enters the tubule through which substances are added to or removed from it. The remaining fluid at the end of each nephron drains into the collecting ducts and exits the kidney as urine.

![Gross anatomy of the kidney](image)

**Figure 1.1:** Gross anatomy of the kidney
[Adapted from Widmaier et al., 2006]

1.1.1.a Renal Corpuscle

Each renal corpuscle is constituted by *glomerulus* (also called glomerular capillaries) and *Bowman’s capsule* (Figure 1.2). The glomerulus is a compact tuft of interconnected capillary loops with a diameter of approximately 200μm, and the Bowman’s capsule is a fluid-filled capsule into which the glomerulus protrudes into. The part of Bowman’s capsule in contact with the glomerulus becomes pushed inwards without touching the opposite side of the capsule, forming a fluid-filled space, known as *Bowman’s space*, within the capsule. As blood flows through the glomerulus from the
Figure 1.2: Renal corpuscle and the ultrafiltration process
[Adapted from Widmaier et al., 2006]
afferent arteriole, about 20 percent of the protein-free plasma filters into Bowman’s space while the remaining blood leaves the glomerulus via the efferent arteriole.

A filtration barrier separates the blood in the glomerulus from the glomerular filtrate in Bowman’s space. This physical barrier is made up of three layers, namely the single-celled capillary endothelium, basal lamina (a noncellular proteinaceous layer of basement membrane, and podocytes (a single-celled epithelial lining of Bowman’s capsule). The podocytes are specialised cells that have an octopus-like structure with a large number of foot processes. The fluid is filtered through the endothelial cells, the basal lamina, and finally between the foot processes of the podocytes (Widmaier et al., 2006).

1.1.1.b The tubules

The tubule is continuous with a Bowman’s capsule. It is hollow and cylindrical in shape with a single layer of epithelial cells. As illustrated in Figure 1.3, the tubule is divided into few segments, namely the proximal tubule, the loop of Henle, and the distal convoluted tubule. Fluid course from the distal convoluted tubule into the collecting duct system that is made up by the cortical collecting duct and medullary collecting duct. Finally, the urine drains into the kidney’s central cavity, the renal pelvis, which is continuous with the ureter (Widmaier et al., 2006).

The proximal tubule comprises of a convoluted portion and a straight portion. The luminal surface of the epithelial cells of the proximal tubule is lined by microvilli to enhance reabsorption processes. The loop of Henle is a sharp, hairpin-like loop comprising a descending limb and an ascending limb (Widmaier et al., 2006). In the collecting ducts, principal cells (P cells) and intercalated cells (I cells) are part of the epithelial cells with the P cells predominating. The P cells involve in the Na⁺ ion and vasopressin-stimulated water reabsorption, whereas the I cells are responsible for H⁺ secretion and HCO₃⁻ ion transport (Ganong, 1999).
Figure 1.3: Nephron
[Adapted from Widmaier et al., 2006]
There are two important regions in the kidney. The outer region is called the renal cortex, and the inner region is the renal medulla that is further divided into three zones, namely the outer stripe of the outer medulla, the inner stripe of the outer medulla, and the inner medulla. All the renal corpuscles are located within the cortex whereas the loops of Henle extend at varying lengths from the cortex down into the medulla giving rise to two different types of nephrons, the cortical and juxtamedullary nephrons. Cortical nephrons are the majority type with 85% share. Their renal corpuscle are located in the outer cortex, and their loops of Henle are short and do not penetrate deep into the medullary region. On the other hand, the renal corpuscles of the juxtamedullary nephrons are found closest to the cortical-medullary junction, and their loops extend deep into the medulla. These long extending loops produce an osmotic gradient by generating a hypertonic medullary interstitium for the reabsorption of water (Widmaier et al., 2006).
1.1.2 Renal circulation

The kidney is a highly vascularised organ, and it receives approximately a quarter of the cardiac output, which is about 1200 – 1300 ml.min\(^{-1}\) of blood. All the four different regions of the kidney are perfused not equally; average total tissue blood flow in the renal cortex is 700 ml.min\(^{-1}\).100 g\(^{-1}\), near the junction of the cortex and the outer medulla is 300 ml.min\(^{-1}\).100 g\(^{-1}\), in the inner stripe of the outer medulla is 200 ml.min\(^{-1}\).100 g\(^{-1}\), and in the inner medulla is between 50 to 100 ml.min\(^{-1}\).100 g\(^{-1}\) (Aukland, 1980; Knox et al., 1984; Cupples, 1986). The blood enters the kidney through the renal artery that arises from the abdominal aorta and leaves the kidney by the renal vein, both at the hilum, respectively. The renal artery branches out into the smaller interlobar artery, the arcuate artery, the interlobular artery, the afferent arteriole, the glomerulus, the efferent arteriole, and peritubular capillary. From here onwards, the blood vessels merge to form bigger vessels, the interlobular veins and eventually the renal vein (Widmaier et al., 2006).

The renal circulation is unique in such a way that it includes two sets of arterioles (afferent and efferent arterioles) and two sets of capillaries (glomerulus and peritubular capillaries). The afferent arterioles (preglomerular arterioles) are short branches of interlobular arteries and they divide into capillary vessels to form the glomerulus. The capillaries coalesce to form the efferent arterioles (postglomerular arterioles), which in turn break up into either the peritubular capillaries that surround the tubules in the cortical nephron or form long hairpin loops of capillaries, known as vasa rectae, that loop deeply into the medulla along side the loops of Henle of the inner cortical and juxtamedullary nephron (Ganong, 1999; Widmaier et al., 2006). As illustrated in Figure 1.4, the efferent arterioles of the juxtamedullary nephrons enter the outer stripe of the outer medulla and divide into vasa rectae that descend into the inner stripe of the outer medulla and form vascular bundles. The descending vasa rectae (DVR) in the centre of the bundles continue into the inner medulla whereas the DVR on the outer margins of the bundles give rise to a capillary plexus between the vascular
bundles in the outer medulla. The DVR found in either the outer or inner medulla divide and eventually coalesce into ascending vasa recta that carry reabsorbed solutes and water from the medulla back into the venous circulation (Kriz, 1981). Approximately 90% of the renal blood flow remains in the renal cortex and perfuses the peritubular capillary bed. The remaining 10% of the blood flow perfuses the renal medulla through the vasa rectae (Kriz, 1981; Zimmerhackl et al., 1987; Cupples et al., 1988).

**Figure 1.4:** Renal microcirculation into the regions of renal cortex (C), the outer stripe of the outer medulla (OS), the inner stripe of the outer medulla, and the inner medulla (IM). Arterial vessels, descending vasa recta (DVR), and capillaries are depicted on the left; the ascending vasa recta and venous circulation are in the middle; and the renal tubular system on the right. [adapted from Mattson, 2003]
1.1.2.a Renal regional circulation

Several functional studies have demonstrated that the blood flow in the renal medullary circulation can indeed be regulated independently of renal cortical blood flow. Such studies have shown that renal medullary blood flow increases after an elevation in renal perfusion pressure despite efficient autoregulation of renal blood flow, renal cortical blood flow, and glomerular filtration rate (Mattson et al., 1993; Cowley, 1997; Evans et al., 2000). The mechanisms that allow modulation of renal medullary blood flow in the absence of changes in renal cortical perfusion are not clear, but evidence obtained from both morphological and physiological studies indicates that the appropriate regulatory components exist in the medullary circulation that makes it possible for the blood flow in this part of the kidney to be selectively regulated.

The afferent and efferent arterioles are small resistance vessels that regulate renal microcirculation and glomerular filtration. Helou and Marchetti (1997) have described two subpopulations of efferent arterioles that display morphological, topological, and functional differences. Morphologically, muscular efferent arterioles (mEA) have a thick, regular, and muscular wall, and terminate as vasa rectae. The mEA of the juxtamedullary nephrons descend into the outer medulla and branch into the vasa rectae in the outer stripe of the outer medulla. These efferent arterioles contain up to four layers of smooth muscle and a layer of endothelial cells. The endothelial cell layer is continuous from the efferent arterioles to the vasa rectae, but the smooth muscle of the efferent arterioles is gradually replaced by pericytes as the vasa rectae divide and branch in the medulla (Kriz, 1981). Pericytes are cells with a phenotype similar to that observed in vascular smooth muscle (Herman and D'Amore, 1985; Nehls and Drenckhahn, 1991; Park et al., 1997), and are found in both the outer and inner medulla (Park et al., 1997). Cultured pericytes have been shown capable of contracting both tangentially and circumferentially (Murphy and Wagner, 1994), and this makes the pericytes ideally suited to modulate blood flow in the vasa rectae by
altering vessel diameter, and provides a mechanism by which medullary blood flow can be regulated in response to circulating hormones or locally released paracrine and autocrine factors (Mattson, 2003). On the other hand, thin efferent arterioles (tEA) have a thinner, irregular and less muscular wall, and terminate as peritubular capillaries. Based on functional aspect, in response to angiotensin II (Ang II), mEA display higher increases in intracellular Ca\(^{2+}\) concentration than tEA, but mEA are slightly less sensitive to Ang II than are tEA (Helou and Marchetti, 1997; Helou et al., 2003). However, mEA from juxtamedullary nephrons in AT\(_{1A}\) receptor-null mice do not exhibit a contractile response under Ang II stimulation suggesting that mouse mEA are devoid of AT\(_{1B}\) receptors (Harrison-Bernard et al., 2003).

Studies using isolated and cannulated DVR on vascular constrictor and dilator responses have demonstrated that the vascular diameter of the DVR can be independently altered by various vasoactive agents involving among others, changes in intracellular calcium and nitric oxide, and cell signalling pathways (Pallone, 1994; Silldorff et al., 1996; Pallone et al., 2000; Rhinehart and Pallone, 2001; Zhang et al., 2002). These studies further establish that the regulation of blood flow within the renal medulla is independent of changes in renal cortical vascular resistance.

1.1.2.b Autoregulation of renal circulation

Renal blood flow can be altered by many conditions, among others are normal physiological changes such as exercise, pain, heat and posture, and diseases that result in decreased or loss of renal tissues, or changes in the arterioles and glomerular capillaries such as hypertension and diabetes mellitus (De Wardener, 1969). The renal microvessels have the ability to autoregulate the total and regional renal blood flow (RBF) to maintain the optimum perfusion pressure by contracting upon pressure rise and dilating upon pressure drop (Johnson and Intaglialetta, 1976). This is because the intrarenal blood flow is very important for normal renal functions and any alteration to blood flow will in turn affect the renal function (Regan et al., 1995).
Renal autoregulation can be defined as the kidney’s ability to alter its own vascular resistance in response to changes in arterial pressure to maintain essentially constant RBF and glomerular filtration rate (GFR) over a range of arterial pressure from 90 to 180 mmHg (Cupples, 1993). Glomerular capillary pressure (P_{gc}) is a function of the balance between afferent and efferent vascular resistances, as well as the level of systemic blood pressure. Increased P_{gc} has been suggested to be a major pathogenetic factor in the development of glomerular sclerosis in hypertensive renal disease in rats (Ofstad et al., 1992). Lowering of the increased P_{gc} has been shown to attenuate glomerular degeneration and preserve renal function (Anderson et al., 1986; Jackson and Johnston, 1988; Brunner et al., 1989; Tolins and Raij, 1990; Wenzel et al., 1992; Dworkin et al., 1993; Griffin et al., 1994, 1995). Adjusting the renal vascular resistance, mainly involving the afferent vessels, may prevent variations in P_{gc} during everyday transitory fluctuations of the systemic blood pressure (Navar, 1978). In experimental conditions, autoregulation keeps both RBF and P_{gc} constant within a wide range of acute pressure variations. When hypertension becomes chronic, the autoregulation is reversibly reset toward higher blood pressures, whereas the capacity of autoregulation seems to be maintained (Iversen et al., 1987). However, an increase in P_{gc} seems to follow long-standing hypertension (Iversen et al., 1998). Among the many controllers of volume and sodium excretion (Dietz et al., 2001; Gabrielsen et al., 2001; Lohmeier et al., 2001; Peterson et al., 2001; Andersen et al., 2002; Schou et al., 2002), blood pressure appears to be among the most potent (Mattson, 2003). When in the well-hydrated state, the renal medullary circulation loses its capacity to autoregulate (Mattson, 2003). Accordingly, hypertension will wash out the osmotic gradient, thereby limiting the amount of fluid excreted.

Autoregulation of RBF is mediated by a rapid myogenic response and a slower tubuloglomerular feedback mechanism (TGF). The myogenic response is, to some degree, an opened-loop mechanism meaning that the local vasoaction will not directly feedback onto the input signal. Conversely, TGF operates in a closed-loop mode. The
TGF responds with a frequency of 0.02 to 0.06 Hz, and has a half-life of roughly 10 to 30 s, whereas the myogenic response is quicker, acting in a range between 0.1 and 0.3 Hz with a half-life of 1 to 4 s (Moore, 1984; Schnermann and Briggs, 1989; Holm et al., 1990; Moore and Casellas, 1990; Holstein-Rathlou et al., 1991; Holstein-Rathlou, 1993; Janssen et al., 1995; Cupples and Loutzenhiser, 1998; Just et al., 1998; Walker et al., 2000; Wang et al., 2000). Both mechanisms due to their different frequency properties, contribute differently to the response to slow and rapid pressure ramps. Slow pressure changes may elicit a predominant TGF response, whereas rapid pressure changes also involve the myogenic response (Flemming et al., 2001).

The key feature that incorporates the TGF simply relates the distal tubule inflow to the afferent arteriolar resistance, such that increases in distal tubular inflow result in vasoconstriction while decreases in flow lead to vasodilation. The distal tubular feedback mechanism mediates autoregulatory adjustments in renal vascular resistance (Navar, 1978). The TGF is known to reset during sustained alterations of arterial pressure (Selen and Persson, 1983), and it has been demonstrated that Ang II, at concentrations that do not alter renal resistance, increases the magnitude of TGF response (Ploth et al., 1979; Mitchell and Navar, 1988). Ang II blockade prevents resetting of autoregulation to operate at lower arterial pressure and RBF, and also impairs operation of the TGF (Cupples, 1993). This finding is compatible with an attenuation of TGF during ACE inhibition (Sorenson et al., 2000). It has been shown that TGF responses were also absent in ACE-deficient (Traynor et al., 1999) as well as in AT1A receptor-deficient (Schnermann et al., 1997) mice, and could be restored to near-normal levels with Ang II (Traynor et al., 1999). Feldberg et al. (1995), using simulation studies, concluded that the myogenic response is a prerequisite to obtaining any degree of autoregulation of RBF by the TGF mechanism. On the contrary, myogenic oscillations can be present when TGF is absent (Navar, 1998).

Resetting of the RBF autoregulation serves to protect the glomerular capillaries from the variations of the systemic pressure. When arterial pressure is reduced
acutely, the magnitude of TGF response also decreases proportionally (Schnermann and Briggs, 1989) but recovers to control levels after 20 minutes despite continuing low pressure (Selen and Persson, 1983). Moreover, Holm et al., (1990) have shown that release of a suprarenal aortic clamp causes a short-lived hyperaemia followed by profound renal vasoconstriction that decays over 20 minutes. The vasoconstriction could be blocked by an angiotensin converting enzyme inhibitor, and they concluded that it reflected the operation of autoregulation since the vasoconstriction was pressure induced. It has been reported that the RBF autoregulation curve was reset toward higher pressure values during acute renal sympathetic nerve stimulation in dogs (Holdaas et al., 1981), hypertensive young SHR (Azar et al., 1979), and the non-clipped kidney in two kidney-one clip (2K1C) hypertensive rats (Iversen et al., 1986). It is possible that resetting of blood flow autoregulation is a general mode of reaction when the perfusion pressure is increased, and it is expected to be a continuous process during the development of systemic hypertension.

Renal tissue damage does influence the resetting of the autoregulation. The resetting of RBF autoregulation seems to be perfect in hypertensive young spontaneously hypertensive rats (SHR) where the glomerular capillary pressure is kept normal (Azar et al., 1979, Iversen et al., 1987). However, in 36-week-old SHR, the glomerular capillary pressure is slightly increased when compared with age-matched WKY (Bank et al., 1983) indicating less perfect resetting of the autoregulation in SHR, possibly because of the greater tissue damage. Nephron loss increases the glomerular capillary pressure in the remnant nephrons (Azar et al., 1977). The glomerular capillary pressure has also been reported to be elevated in the non-clipped kidney in the 2K1C rat (Steiner et al., 1982), the DOCA-salt hypertensive rats (Dworkin et al., 1982), and in the Milano hypertensive rats (Baer and Bianchi, 1978).

Animal experiments have demonstrated significantly different effects of antihypertensive drugs on RBF autoregulation. Calcium channel blockers abolish RBF autoregulation (Navar et al., 1986) by eliminating the macula densa response (Mitchell
and Navar, 1990) whereas preserved autoregulation during resetting, caused by treatment with α1-adrenoceptor blocker and angiotensin converting enzyme inhibitor were observed (Navar et al., 1986; Iversen et al., 1987; Kvam et al., 1998). Hence, it is important that the preferable antihypertensive agents should not only reduce arterial blood pressure but also preserve RBF autoregulation and a normal $P_{gc}$. Antihypertensive drugs that abolish RBF autoregulation could be deleterious to the kidney if the systemic blood pressure is not reduced sufficiently.

1.1.3 Role of the kidney in the long-term regulation of arterial pressure

The theoretical importance of the kidney in the control of arterial pressure and the concept that alterations in renal function lead to adjustments in arterial blood pressure was first introduced by Guyton and colleagues (1974). Although arterial blood pressure is controlled by many regulatory systems, it is proposed that the kidney, through its ability to regulate extracellular fluid volume, is the dominant long-term controller of arterial pressure (Guyton et al., 1999). A key feature of this control system is pressure natriuresis, or the ability of the kidneys to respond to changes in arterial pressure by altering the renal excretion of salt and water (Reinhart et al., 1995; Lohmeier et al. 2000).

The importance of the renal capacity to excrete sodium and water for the level of sustained arterial pressure of an organism has been revealed by system analyses of arterial pressure regulation (Guyton et al., 1999). Support for the important role of the kidney for long-term arterial pressure regulation, and for the development and maintenance of genetic forms of arterial hypertension comes from renal transplantation studies in patients and experimental animals (Rettig et al., 1993, 1996). Renal transplant studies performed between hypertensive and normotensive strains of rats have demonstrated that the long-term level of arterial pressure in the recipient is dependent on the genetic background of the donor kidney. Transplantation of the kidney from the SHR, the Dahl salt-sensitive rat, the Milan hypertensive rat, the stroke-
prone SHR, and the Prague hypertensive rat into histocompatible normotensive 
recipients induces arterial hypertension in the recipient (Cowley, 1992; Rettig et al., 
1993; Mattson and Cowley, 1999). The opposite experiments have also been 
successfully performed where the kidney from normotensive donor rats transplanted 
into bilaterally nephrectomized SHR combined with immunosuppression lowers arterial 
blood pressure in SHR (Patschan et al., 1997).

Following transplantation of a kidney from young SHR donors into 
normotensive histocompatible recipients, hypertension develops within a few weeks 
and reaches a stable level within 6 – 8 weeks after renal transplantation (Rettig et al., 
1990). The development of renal post-transplantation hypertension is associated with 
increased renal sodium retention (Graf et al., 1993). Other mechanisms involve in the 
pathophysiology of post-transplantation hypertension remain unclear. Studies on renal 
plasma flow and GFR (Rettig et al., 1990), renal and plasma renin-angiotensin systems 
(Rettig et al., 1994), and renal α-adrenoceptor density (Michel et al., 1992) do not show 
differences in the respective traits that could be associated with this form of 
hypertension. Also, there is no sympathetic reinnervation of the grafted kidney during 
the development of renal post-transplantation hypertension, thus the effects of the 
recipients sympathetic nervous system are of limited importance for the development 
of renal post-transplantation hypertension (Grisk et al., 2000).

Clinical studies have produced similar data, and it was first demonstrated that in 
patients who received a renal transplant from a donor with a family history of 
hypertension, mean arterial pressure was significantly higher than in patients whose 
donor family had a normotensive history (Guidi et al., 1996). Whereas, patients who 
received a transplant from a hypertensive donor had higher blood pressures compared 
with patients who received kidneys from normotensive donors (Strandgaard and 
Hansen, 1986). Finally, transplantation of a kidney from a normotensive donor 
produced a sustained normalisation of arterial pressure in hypertensive patients who 
had demonstrated long-standing essential hypertension (Curtis et al., 1983). These
clinical data emphasize the importance of the kidney in the development and maintenance of hypertension in humans and experimental animals.

Transplant studies have established the role of the kidney in arterial blood pressure regulation, but the intrinsic renal mechanisms that regulate arterial pressure are not revealed by these experiments. The kidney could influence blood pressure regulation by altering renal afferent nerve activity (DiBona and Koop, 1997), releasing vasoactive factors into the circulation (Bergstrom et al., 1998), or by altering extracellular fluid volume through a number of different mechanisms (Cowley and Roman, 1996). Chronic alterations in renal adrenergic activity achieved either by renal denervation or long-term infusions of norepinephrine directly into the renal artery, alter pressure natriuresis and produce sustained changes in arterial pressure (Reinhart et al., 1995; Lohmeier et al. 2000).

1.1.3.a Medullary circulation in the long-term regulation of arterial pressure

The renal medulla receives only a small fraction (10%) of total renal blood flow, and the flow per unit of tissue weight is only approximately 30 – 60% of that in the cortex (Pallone et al. 1990, 2000), yet its microcirculation appears to play a critical role in the long-term maintenance of arterial pressure via its influence on sodium and water reabsorption (Cowley, 1997; Bergstrom and Evans, 2000). This appears to be mediated mainly through the influence of medullary blood flow (MBF) on tubular reabsorption of salt and water (Cowley, 1997).

Based on pharmacological studies, it has been suggested that changes in blood flow in the renal medulla is an important mechanism in the regulation of sodium and water excretion, and dilation of the renal medullary circulation can have a natriuretic and/or diuretic effect (Lameire et al., 1980; Fadem et al., 1982). A direct increase in renal perfusion pressure (RPP) leads to an increased sodium and water excretion in the isolated perfused kidney (Aperia et al., 1971; Tobian et al., 1978), and kidneys studied in vivo (Roman and Cowley, 1985; Roman, 1988; Roman et al., 1988;
RBF or GFR. In addition, the hydrostatic pressure in the postglomerular capillaries in
the renal cortex, the peritubular capillaries, is also constant as RPP is increased
(Roman and Cowley, 1985; Roman et al., 1988). However, blood flow in the vasa recta
capillaries of the renal medulla was demonstrated to increase directly with RPP despite
the autoregulation of GFR and RBF in normal mice, rats, and dogs (Roman et al.,
1988; Strick et al., 1989; Farrugia et al., 1993; Mattson et al., 1993; Huang et al., 1994;
Bergstrom et al., 1998; Gross et al., 1998a, 1998b). The increase in flow in the vasa recta
capillary bed in the renal medulla is coincident with an increase in vasa recta
hydrostatic pressure (Roman et al., 1988), increased renal interstitial hydrostatic fluid
pressure (Roman et al., 1988; Garcia-Estan and Roman, 1989; Patel et al., 1994),
decreased reabsorption of sodium and water from the proximal segments of deep
nephrons (Haas et al., 1986; Roman, 1988), and increased excretion of sodium and
water (Roman and Cowley, 1985; Roman et al., 1988).

Experiments by Mattson et al., (1994) and Makino et al., (2002) have shown
that a selective and sustained decrease in medullary perfusion can lead to retention of
sodium and development of hypertension. Continuous renal medullary interstitial
infusion of L-NAME in the normotensive Sprague-Dawley rats significantly decreased
renal medullary blood flow by 30%, and was accompanied by a significant retention of
sodium, an increase in body weight, and the development of hypertension. Renal
medullary blood flow returned to normal levels, a negative sodium balance was
observed, and blood pressure returned to levels not different from control when the
interstitial L-NAME infusion was discontinued (Mattson et al., 1994) without any change
in renal cortical blood flow (Makino et al., 2002).

Changes in resistance in renal cortical vessels can also have a profound impact
on blood flow to the medulla as any change in inflow resistance will be reflected in
blood flow in the downstream segments of the renal medulla, and the likely sites
involved are the preglomerular resistance vessels, i.e. the afferent arterioles (Mattson,
2003). In summary, the medullary circulation is important in the long-term regulation of fluid and electrolyte balance, and blood pressure. Direct long-term alterations in renal medullary blood flow can lead to changes in sodium and water excretion which may be translated into sustained alterations in sodium balance and a new level of arterial blood pressure.

1.1.3.b Influences of Ang II on renal medullary circulation.

Renal vessels, in general, and especially in SHR are more sensitive to catecholamines, Ang II, and also calcium channel blockers (CCBs) than the systemic resistance vessels (Loutzenhiser and Epstein, 1990). The CCBs affect mainly the afferent arteriole (Fleming et al., 1987; Cacellas and Moore, 1990) and so do the $\alpha_1$-adrenoceptor blocker. Both, Ang II and catecholamines, have been shown to constrict preglomerular vessels in isolated arteries (Edwards, 1983), in isolated kidneys (Steinhausen et al., 1990), and in vivo (Chatziantoniou and Arendshorst, 1992). Similar to Ang II, nervous stimulation has been reported to affect both afferent and efferent resistances (Hermansson et al., 1981). The effect of nervous stimulation also be facilitated by increased Ang II levels as Ang II is an important mediator of the contraction of resistance vessels during nervous stimulation in rats (Pelayo et al., 1984).

Ang II is a major mediator of the regulation of glomerular filtration through its combined control of the vascular tone in both arterioles. Ang II has been shown to have a vasoconstrictor effect on the renal medullary circulation (Faubert et al., 1987; Pallone, 1994), no influence on the medullary circulation (Mattson et al., 1991; Mattson and Roman, 1991), or even an increase in medullary blood flow with high doses of Ang II (Nobes et al., 1991). Prostaglandin (Cupples et al., 1988; Mattson and Roman, 1991; Pallone, 1994), nitric oxide (Zou et al., 1997; Szentizvanyi et al., 1999, 2002), and kinins (Nobes et al., 1991) attenuate the vasoconstrictor action of Ang II in the medullary circulation. Szentizvanyi et al. (2002) reported an inherited defect in the
ability of Dahl salt-sensitive rat to produce nitric oxide within the outer medulla of the kidney along with a failure of medullary nitric oxide concentrations to increase in response to Ang II in this strain. As a result, small elevations of circulating Ang II that have no effect in normal rats lead to hypertension in Dahl salt-sensitive rats.

The net effect of Ang II on blood flow in the renal medulla in vivo appears to be due to increased resistance in the efferent arterioles of the juxtamedullary nephrons (Carmines et al., 1986) and/or due to direct effects of Ang II to constrict the DVR (Pallone, 1994). Yet, the net effect of changes in circulating Ang II in the physiological range on medullary blood flow in conscious rats is minimal (Gross et al., 1998), possibly due to antagonistic actions of different vasodilatory factors.

In addition, the mechanism of the decrease in medullary blood flow appears to be due to a combination of a reduction in renal cortical blood flow (Leonard et al., 2000) as well as direct actions of norepinephrine to vasoconstrict the DVR (Yang et al., 1995). Pharmacological studies have demonstrated that the sympathetic neurotransmitter norepinephrine decreases renal medullary perfusion via stimulation of $\alpha_1$-adrenoceptors (Zou and Cowley, 2000).

1.1.4 Renal innervation

The sympathetic nervous system (SNS) plays an important role in arterial pressure regulation. This system regulates the total and regional peripheral resistance and capacitance of the vascular system mainly through changes following release of catecholamines from both the sympathetic nerve terminals and the adrenal medulla gland (Guimaraes and Moura, 2001), and binding of the catecholamines to the adrenergic receptors.

The mechanisms by which the SNS regulates arterial pressure acutely and chronically are quite different (Guyton, 1980), hence, acute blood pressure responses to either sympathetic stimulation or inhibition may not be generalised into the contribution of the SNS to the chronic maintenance of arterial pressure. The activity of
the SNS is important for rapid adjustments of cardiovascular and renal function in response to changing environment conditions. Its involvement in long term arterial pressure regulation remains unclear due to a lack of reliable methods or technical limitations to chronically quantify sympathetic activity, and adaptation of the nervous system to repeatedly applied stimuli, for example, central and peripheral resetting of baroreflexes, and to determine the sustained influence of the sympathetic nervous system on sodium excretion (Lohmeier et al., 2001). Numerous acute studies demonstrating that Ang II actually increases sympathetic activity (Reid, 1992; Fink, 1997), but yet it is fascinating to discover that chronic baroreflex-mediated suppression of renal sympathetic nervous activity (RSNA) is the compensatory response to Ang II hypertension leading to attenuation of the antinatriuretic and hypertensive effect of Ang II (Carrol et al., 1984; Cox and Bishop, 1991; Lohmeier et al., 2001). However, there is little chronic data to support the contention that the sympathetic nervous system contributes to Ang II hypertension (Reid, 1992; Fink, 1997).

In addition to short lasting effects on organ function, the sympathetic nervous system may also induce chronic effects on target organs, manifested as altered DNA, protein synthesis and changes in organ morphology. SHR are characterised by increased sympathetic innervation of their internal organs compared to normotensive animals. Selective surgical renal denervation in young SHR delays, but does not prevent, the development of arterial hypertension, and complete neonatal sympathectomy induces a long term reduction of arterial pressure in SHR. Hence, of how reduction in sympathetic tone affects long term blood pressure in SHR is dependent on the stage during ontogeny at which it is applied, and on the extent to which sympathetic influences are removed. The specific organ affected is also a contributing factor. Since the kidney appears to be the major determinant of long term blood pressure in SHR, studying the specific role of early sympathetic activation within this organ for the development of hypertension in this model is a prospect to consider.
The kidney has very dense sympathetic innervations, and neuroeffector junctions have been described along most of the vascular and tubular elements of the tissue (Coote et al., 1972; Johns et al., 1976). Renal sympathetic nerve activity (RSNA) plays a significant role in the regulation of renal haemodynamics and excretory function (Malpas et al., 1996; DiBona and Koop, 1997; Malpas and Evans, 1998; DiBona, 2000; Leonard et al., 2001). Renal nerves modulate RBF variability in several physiological conditions, such as exerting an antihypertensive effect when renal perfusion pressure is reduced, and RSNA is increased during hypoxia or hemorrhage (Janssen et al., 1997; Malpas et al., 1998, 1999; Nafz et al., 2000; Zou and Cowley, 2000; Barret et al., 2001).

At a functional level, high levels of direct electrical stimulation of the renal sympathetic nerves resulted in frequency related decreases in RBF (Sattar and Johns, 1994a, 1994b; Armenia et al., 2004), GFR and renin release (Coote et al., 1972 and Johns et al., 1976). One of the groundbreaking reports was that of LaGrange and his co-workers (1973) who observed that electrical stimulation of the renal nerves at low levels, which had no measurable impact on renal haemodynamics, still caused a large decrease in sodium and water excretion. These observations laid the foundation for the concept that the renal nerves could directly act on the tubular epithelial cells of the proximal tubule (Bello-Reuss et al., 1976) and thick limb of the loop of Henle (DiBona and Sawin, 1982) to increase the rate of fluid transport from lumen to interstitium. Currently, it is considered that graded activation of the renal sympathetic nerves progressively recruits a number of functions, initially stimulating renin release from the granular juxtaglomerular cells; thereafter sodium absorption is raised; while at the highest rates reductions in blood flow and glomerular filtration occur (Osborn and Johns, 1989; DiBona and Kopp, 1997). Together, these reports support the view that the neural control of sodium reabsorption by the kidney is exerted at levels that have minimal effects on renal haemodynamics.
RSNA has been shown to be important in the control of total RBF (Malpas et al., 1996; Malpas and Evans, 1998), yet its role in the control of regional kidney blood flow remains unclear. RSNA may have a profound effect on the long-term control of arterial pressure mediated via effects on the medullary microcirculation. In addition to the multiple effects of sympathetic nerve stimulation on kidney function (DiBona and Koop, 1997), renal nerve stimulation differentially decreases blood flow in the renal cortex and medulla (Rudenstam et al., 1995; Leonard et al., 2000, 2001). The renal nerves might differently regulate cortical (or total renal) blood flow (CBF) and MBF through different frequency response characteristics of the vasculature in these two regions. MBF appears to be less sensitive to sympathetic nerve activity than CBF, regardless of whether the nerves are activated by electrical stimulation (Leonard et al., 2000) or reflexively (Leonard et al., 2001), but sensitivity within these vascular territories appears to be relatively homogenous (Guild et al., 2002).

The medullary insensitivity is particularly evident at relatively low stimulus intensities, as might occur under physiological conditions (Rudenstam et al., 1995; Leonard et al., 2000, 2001) despite juxtamedullary efferent arterioles (mEA) having more layers of smooth muscle cells (Kriz, 1981; Helou and Marchetti, 1997; Pallone et al., 1998), and denser innervation (Gorgas, 1978) than superficial or outer cortical efferent arterioles. This may be due to the influence of $\alpha_2$-receptor stimulation by norepinephrine in the medulla to increase the release of NO, which opposes the vasoconstrictor effects of norepinephrine (Zou and Cowley, 2000). Also, differences in the density and organization of vascular network and vascular structure (Kriz, 1981; Pallone et al., 1990), density and distribution of innervations (Barajas and Powers, 1990), or the kinetics of smooth muscle contraction between cortical and medullary vascular sites may result in a difference in the ability to respond to the different frequencies in RSNA.

The renal sympathetic nerves represent one primary mechanism by which kidney fluid reabsorption can be modulated, and via the consequent increase or
decrease in extracellular fluid volume can have a major impact on blood pressure. The renal nerves appear to be the critical link between the SNS and long-term regulation of arterial pressure, because they impact renal excretory function (Guyton, 1980). Sympathetic nervous system responds chronically, as well as acutely, to regulate body fluid volumes and arterial pressure. It has been demonstrated that suppression of RSNA and attendant increments in renal excretory function are long-term responses to excess body fluid volumes and hypertension (Lohmeier and Hildebrandt, 1998; Lohmeier et al., 1998, 1999, 2000). During high salt intake or hypertension induced by chronic intravenous infusion of either norepinephrine or Ang II, there is a relative increase in sodium excretion from innervated as compared to denervated kidneys (Lohmeier and Hildebrandt, 1998; Lohmeier et al., 1998, 1999, 2000). This indicates that RSNA is suppressed in these states of chronic volume excess and/or hypertension.

It has also been determined that the chronic suppression of RSNA in Ang II hypertension is abolished by denervation of sinoaortic and cardiopulmonary baroreceptors, suggesting that baroreflexes play a critical role in the long-term response (Lohmeier et al., 2000). Subjecting rats to coartation of the aorta to produce an abrupt and constant increase in arterial pressure, and from recording of aortic baroreceptor activity during anaesthesia, Krieger (1986) concluded that complete baroreceptor resetting occurs within 48 hr of hypertension. Another study by Cowley and DeClue (1976), by inducing a rapid and sustained increase in arterial pressure by chronic infusion of Ang II in dogs with and without sinoaortic denervation, showed that acute increases in arterial pressure in response to Ang II were more pronounced after deafferentation of arterial baroreceptors than before when the arterial baroreflex was intact. However, the increase in blood pressure was equal in both groups, and finally the arterial pressures on day 7 of Ang II infusion were comparable. Thus, the baroreceptors appeared to have no sustained influence on the severity of the